Abcam plc
What makes a good potential target for drug discovery? Listen in as Dr. Elizabeth Glennon, of King's College London, discusses how the disruption of axonal transports early on within Alzheimer's Disease provides excellent targets for drug discovery. How the disruption of axonal transport contributes to the development of Alzheimer's disease. Mechanisms of axonal transport of the Alzheimer's amyloid precursor protein, and how these are altered in the disease.
Watch Now
The modern trial strategies of today accommodate for a more modern, patient-focused approaches inclusive of the needs of sites and patients.
Watch Now
Neoteryx
On Tuesday, June 25th, at 10:00 AM EDT, 4:00 PM CEST, Neoteryx, The Medicine Maker, and two leading blood microsampling experts present The Science of Smarter Sampling for Drug Development, an in-depth hour-long webinar covering the details of how to succeed with blood microsampling technology in the analytical lab.
Watch Now
fiercepharma
Today, there are clear signs that the biopharmaceutical industry is facing a quiet yet potentially damaging force: compressive disruption. However, future-focused biopharma companies have found a way to deliver exceptional growth amidst compressive disruption: by embracing New Science, an ever-evolving combination of the best in science and health technology that is filling unmet need and raising the standard of care. Accenture research finds that leaders in New Science are investing 6-7x more in digital, data and genomics compared to their peers.
Watch Now